Mylan

Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap
Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap
Fierce Pharma
Novartis
Mylan
Pfizer
EpiPens
Sandoz
Symjepi
drug launches
Adamis Pharmaceuticals
Flag link:
Supply constraints push EpiPen rival maker Amneal to restructure, shares fall
Supply constraints push EpiPen rival maker Amneal to restructure, shares fall
Endpoints
Amneal
Mylan
EpiPens
generics
Flag link:
With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger
With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger
Fierce Pharma
FDA
Biocon
Mylan
Sanofi
Lantus
insulin
drug manufacturing
Flag link:
Mylan investors favor expanding exec pay clawbacks. Will the company listen?
Mylan investors favor expanding exec pay clawbacks. Will the company listen?
Fierce Pharma
Mylan
executive pay
Flag link:
House progressives challenge drugmakers to come back to Capitol Hill
House progressives challenge drugmakers to come back to Capitol Hill
Stat
Democrats
drug pricing
Pfizer
Merck
Eli Lilly
Gilead Sciences
Mylan
Mallinckrodt
Flag link:
[sponsored] Life Sciences Matchmaker SOURCE EXPLORER Passes 3,000-Client Milestone

[sponsored] Life Sciences Matchmaker SOURCE EXPLORER Passes 3,000-Client Milestone

CP Wire
life sciences
Source Explorer
Gilead Sciences
Roche
Mylan
Biogen
Genentech
AstraZeneca
Flag link:
[sponsored] Life Sciences Matchmaker SOURCE EXPLORER Passes 3,000-Client Milestone

life sciences
Source Explorer
Gilead Sciences
Roche
Mylan
Biogen
Genentech
AstraZeneca
Flag link:
Hurting for revenue, Mylan shells out $130M for basket of Aspen drugs
Hurting for revenue, Mylan shells out $130M for basket of Aspen drugs
Fierce Pharma
Mylan
Aspen Pharmacare
M&A
Australia
New Zealand
Flag link:
Medicaid misclassification bill inspired by EpiPen snafu passes Congress
Medicaid misclassification bill inspired by EpiPen snafu passes Congress
Fierce Pharma
Mylan
generics
EpiPen
Medicaid
congress
misclassification
Flag link:
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
After Alzheimer’s collapse, Biogen must win Tecfidera patent challenge
EP Vantage
Biogen
Alzheimer's disease
Tecfidera
generics
Mylan
Flag link:
Mylan and Hospira both recall injected drugs after particulate discovered in vials
Mylan and Hospira both recall injected drugs after particulate discovered in vials
Fierce Pharma
Mylan
Hospira
recalls
diabetes
chemotherapy
Flag link:
Mylan's Advair generic pressures GSK with strong launch
Mylan's Advair generic pressures GSK with strong launch
BioPharma Dive
GSK
Mylan
generics
Advair
Wixela Inhub
Flag link:
What's Behind Mylan's Disappointing Q4 Earnings?
What's Behind Mylan's Disappointing Q4 Earnings?
Motley Fool
Mylan
earnings
Flag link:
Teva aims for 25% of U.S. EpiPen market by 2020
Teva aims for 25% of U.S. EpiPen market by 2020
Drug Delivery Business News
Teva Pharmaceutical
Mylan
EpiPen
generics
Flag link:
Mylan launches Advair generic at 70% discount in US
Mylan launches Advair generic at 70% discount in US
Pharmaforum
Mylan
GSK
Advair
generics
Flag link:
Mylan takes step toward knocking down key patent for Biogen's top-seller
Mylan takes step toward knocking down key patent for Biogen's top-seller
Biopharma Dive
Mylan
Biogen
Tecfidera
patents
inter partes review
Flag link:
Mylan’s Generic Advair Breathes New Life into Asthma Market
Mylan’s Generic Advair Breathes New Life into Asthma Market
Xtalks
Mylan
GSK
Advair
generics
FDA
asthma
Wixela Inhub
Flag link:
Mylan finally crosses the finish line with long-awaited generic of GlaxoSmithKline's Advair
Mylan finally crosses the finish line with long-awaited generic of GlaxoSmithKline's Advair
Fierce Pharma
Mylan
GSK
FDA
Advair
generics
Wixela Inhub
Flag link:
UnitedHealthcare, fueled by federal probes, sues generics makers for price fixing
UnitedHealthcare, fueled by federal probes, sues generics makers for price fixing
Fierce Pharma
UnitedHealthcare
generics
price fixing
drug pricing
Mylan
Teva Pharmaceuticals
Sandoz
Actavis
Par Pharmaceutical
Sun Pharma
Aurobindo
Taro Pharmaceuticals
Flag link:
Adamis stock surges on release of EpiPen alternative
Adamis stock surges on release of EpiPen alternative
Marketwatch
Adamis
Mylan
Sandoz
EpiPens
Symjepi
Flag link:

Pages